Published in Circulation on April 21, 2003
Investigating the Role of Luminal Pressure on Arteriovenous Fistula Maturation | NCT04017806
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (2003) 3.19
Uric acid and inflammatory markers. Eur Heart J (2006) 2.81
Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol (2014) 2.48
Reactive oxygen species in cardiovascular disease. Free Radic Biol Med (2011) 2.29
Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health (2004) 2.00
Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy. Heart (2009) 1.49
Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study. Am J Hypertens (2014) 1.48
Serum total antioxidant capacity reflects severity of illness in patients with severe sepsis. Crit Care (2006) 1.45
Influence of urate-lowering therapies on renal handling of uric acid. Clin Rheumatol (2014) 1.44
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study. Int J Cardiol (2009) 1.38
Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J (2011) 1.26
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep (2013) 1.20
Impact of allopurinol use on urate concentration and cardiovascular outcome. Br J Clin Pharmacol (2011) 1.16
Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years. Am J Cardiol (2007) 1.14
Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation (2003) 1.12
The relationship between serum uric acid and spirometric values in participants in a health check: the Takahata study. Int J Med Sci (2011) 1.10
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol (2006) 1.09
Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis (2005) 1.08
Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res (2015) 1.05
The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr (2009) 1.02
Serum uric acid to creatinine ratio in patients with chronic obstructive pulmonary disease. Lung (2007) 0.99
NADPH oxidase has a directional response to shear stress. Am J Physiol Heart Circ Physiol (2008) 0.99
Uric Acid Puzzle: Dual Role as Anti-oxidantand Pro-oxidant. Electrolyte Blood Press (2014) 0.98
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction. Clin Res Cardiol (2011) 0.98
Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS One (2012) 0.95
Uric acid and dementia in community-dwelling older persons. Dement Geriatr Cogn Disord (2009) 0.93
Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One (2010) 0.93
Hyperuricemia and incident heart failure. Circ Heart Fail (2009) 0.92
Inhibition of xanthine oxidase by allopurinol prevents skeletal muscle atrophy: role of p38 MAPKinase and E3 ubiquitin ligases. PLoS One (2012) 0.90
Serum uric acid is more strongly associated with impaired fasting glucose in women than in men from a community-dwelling population. PLoS One (2013) 0.89
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation (2015) 0.89
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Associations Between Hyperuricemia and Chronic Kidney Disease: A Review. Nephrourol Mon (2015) 0.87
Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart (2007) 0.87
Biomarkers for chronic heart failure : diagnostic, prognostic, and therapeutic challenges. Herz (2009) 0.85
Oxidative stress markers and C-reactive protein are related to severity of heart failure in patients with dilated cardiomyopathy. Mediators Inflamm (2014) 0.84
Association between uric acid levels and obstructive sleep apnea syndrome in a large epidemiological sample. PLoS One (2013) 0.84
The interplay between uric acid and antioxidants in relation to physical function in older persons. J Am Geriatr Soc (2007) 0.84
Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart (2005) 0.83
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail (2013) 0.83
Usefulness of combining serum uric acid and high-sensitivity C-reactive protein for risk stratification of patients with metabolic syndrome in community-dwelling women. Endocrine (2013) 0.83
Obesity-related cardiorenal disease: the benefits of bariatric surgery. Nat Rev Nephrol (2013) 0.83
Serum uric acid as an index of impaired renal function in congestive heart failure. J Geriatr Cardiol (2012) 0.83
Vascular endothelial function is not related to serum uric acid in healthy adults. Am J Hypertens (2012) 0.82
Could uric acid have a pathogenic role in pre-eclampsia? Nat Rev Nephrol (2010) 0.81
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
Treatment-related biomarkers in pulmonary hypertension. Am J Respir Cell Mol Biol (2015) 0.80
Uric Acid Induces Endothelial Dysfunction by Activating the HMGB1/RAGE Signaling Pathway. Biomed Res Int (2017) 0.80
Relationship between serum uric acid levels and ventricular function in patients with idiopathic pulmonary hypertension. Exp Clin Cardiol (2013) 0.79
Asymptomatic hyperuricemia: is it time to intervene? Clin Rheumatol (2017) 0.79
Serum uric acid: a forgotten prognostic marker in acute coronary syndromes? Eur Heart J Acute Cardiovasc Care (2013) 0.79
Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure. Korean J Intern Med (2010) 0.79
High Uric Acid Induces Insulin Resistance in Cardiomyocytes In Vitro and In Vivo. PLoS One (2016) 0.79
Cardiac resynchronization therapy guided by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2010) 0.79
Serum uric acid and cardiovascular disease. Maedica (Buchar) (2010) 0.79
The relationship between serum levels of uric acid and prognosis of infection in critically ill patients. World J Emerg Med (2012) 0.79
Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev (2013) 0.78
Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis. J Card Fail (2014) 0.78
Metabolic and immunologic derangements in cardiac cachexia: where to from here? Heart Fail Rev (2006) 0.78
Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovasc Diabetol (2016) 0.78
Nutrition intervention to decrease symptoms in patients with advanced heart failure. Res Nurs Health (2013) 0.77
Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation (2015) 0.77
Serum uric acid levels and cerebral microbleeds in patients with acute ischemic stroke. PLoS One (2013) 0.77
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease. Oxid Med Cell Longev (2016) 0.76
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up. Lipids Health Dis (2013) 0.76
Uric acid and prognosis in chronic heart failure. Circulation (2003) 0.75
Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricema. Blood Coagul Fibrinolysis (2015) 0.75
Evaluation and comparison of biomarkers in heart failure. Indian Heart J (2015) 0.75
Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches? Cell Stress Chaperones (2014) 0.75
Liver Enzymes and Uric acid in Acute Heart Failure. Res Cardiovasc Med (2015) 0.75
Clinical and hemodynamic profiles of elderly patients with pulmonary arterial hypertension: a single center, prospective study. J Geriatr Cardiol (2017) 0.75
Uric acid predicts mortality and ischaemic stroke in subjects with diastolic dysfunction: the Tromsø Study 1994-2013. ESC Heart Fail (2017) 0.75
Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Fail (2016) 0.75
A double blind placebo controlled randomized trial of the effect of acute uric acid changes on inflammatory markers in humans: A pilot study. PLoS One (2017) 0.75
Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia. Heart Vessels (2016) 0.75
Biomarkers in heart failure: a clinical review. Heart Fail Rev (2008) 0.75
Evaluation of human nonmercaptalbumin as a marker for oxidative stress and its association with various parameters in blood. J Clin Biochem Nutr (2017) 0.75
Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. Oxid Med Cell Longev (2017) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Cachexia: a new definition. Clin Nutr (2008) 5.49
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Increased metaboreceptor stimulation explains the exaggerated exercise pressor reflex seen in heart failure. J Appl Physiol (1985) (2007) 4.02
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation (2002) 3.34
Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: single-institution experience in 358 consecutive patients. Ann Thorac Surg (2007) 3.21
Concern Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J (2009) 3.14
Ethical authorship and publishing. Int J Cardiol (2008) 2.97
Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope. Eur Heart J (2005) 2.84
Conventional surgical repair and endovascular treatment of acute traumatic aortic rupture. Eur J Cardiothorac Surg (2007) 2.81
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motion. J Am Coll Cardiol (2009) 2.61
Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J (2012) 2.60
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J (2007) 2.59
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol (2004) 2.29
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J (2009) 2.21
One-year follow-up of very preterm infants who received lucinactant for prevention of respiratory distress syndrome: results from 2 multicenter randomized, controlled trials. Pediatrics (2007) 2.20
Pregnancy after varicocelectomy: impact of postoperative motility and DFI. Urology (2013) 2.20
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Genome-wide prediction of G4 DNA as regulatory motifs: role in Escherichia coli global regulation. Genome Res (2006) 2.12
Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation (2003) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10
Outcomes of HeartWare Ventricular Assist System support in 141 patients: a single-centre experience. Eur J Cardiothorac Surg (2012) 2.09
Nexilin mutations destabilize cardiac Z-disks and lead to dilated cardiomyopathy. Nat Med (2009) 2.08
Effects of a comprehensive blood-sparing approach using body weight-adjusted miniaturized cardiopulmonary bypass circuits on transfusion requirements in pediatric cardiac surgery. J Thorac Cardiovasc Surg (2012) 2.06
Top of the charts: download versus citations in the International Journal of Cardiology. Int J Cardiol (2005) 2.06
Heart failure reversal by ventricular unloading in patients with chronic cardiomyopathy: criteria for weaning from ventricular assist devices. Eur Heart J (2010) 2.06
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2007) 1.99
Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med (2005) 1.99
Clinical relevance of oxidative stress in male factor infertility: an update. Am J Reprod Immunol (2008) 1.98
Is bridge to recovery more likely with pulsatile left ventricular assist devices than with nonpulsatile-flow systems? Ann Thorac Surg (2011) 1.94
Oxidative stress & male infertility. Indian J Med Res (2009) 1.93
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
Statement on authorship and publishing ethics in the International Journal of Cardiology. Int J Cardiol (2011) 1.90
Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol (2012) 1.90
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol (2013) 1.89
Dysfunction of dysferlin-deficient hearts. J Mol Med (Berl) (2007) 1.89
Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost (2005) 1.86
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
Morphometric analysis of aortic media in patients with bicuspid and tricuspid aortic valve. Ann Thorac Surg (2002) 1.86
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol (2002) 1.83
Anemia and inflammation in COPD. Chest (2005) 1.83
Dislocated wrap after previous reduction aortoplasty causes erosion of the ascending aorta. Ann Thorac Surg (2003) 1.83
Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. Eur Heart J (2008) 1.81
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J (2011) 1.81
A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics (2005) 1.80
Contemporary (post-Wills) survey of the views of Australian medical researchers: importance of funding, infrastructure and motivators for a research career. Med J Aust (2005) 1.79
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol (2013) 1.75